CoChat

Allosteric Inhibitor Development Targeting HIV‐1 Integrase

Open access
Al‐Mawsawi, Laith Q., Neamati, Nouri · 2011 · ChemMedChem
Cited by 61

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

HIV‐1 integrase (IN) is one of three essential enzymes for viral replication, and is a focus of ardent antiretroviral drug discovery and development efforts. Diligent research has led to the development of the strand‐transfer‐specific chemical class of IN inhibitors, with two compounds from this group, raltegravir and elvitegravir, advancing the farthest in the US Food and Drug Administration (FDA) approval process for any IN inhibitor discovered thus far. Raltegravir, developed by Merck & Co., has been approved by the FDA for HIV‐1 therapy, whereas elvitegravir, developed by Gilead Sciences and Japan Tobacco, has reached phase III clinical trials. Although this is an undoubted success for the HIV‐1 IN drug discovery field, the emergence of HIV‐1 IN strand‐transfer‐specific drug‐resistant viral strains upon clinical use of these compounds is expected. Furthermore, the problem of strand‐transfer‐specific IN drug resistance will be exacerbated by the development of cross‐resistant viral strains due to an overlapping binding orientation at the IN active site and an equivalent inhibitory mechanism for the two compounds. This inevitability will result in no available IN‐targeted therapeutic options for HIV‐1 treatment‐experienced patients. The development of allosterically targeted IN inhibitors presents an extremely advantageous approach for the discovery of compounds effective against IN strand‐transfer drug‐resistant viral strains, and would likely show synergy with all available FDA‐approved antiretroviral HIV‐1 therapeutics, including the IN strand‐transfer‐specific compounds. Herein we review the concept of allosteric IN inhibition, and the small molecules that have been investigated to bind non‐active‐site regions to inhibit IN function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cmdc.201000443

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

Metadata

Authors
Al‐Mawsawi, L. Q., & Neamati, N.
Venue
ChemMedChem
Publisher
Wiley
Published
2011-01-12
Volume
6
Issue
2
Pages
228-241
ISSN
  • 1860-7179 (ISSN-L)
  • 1860-7187
OpenAlex
W2041532523
Cited by
61
References
19
FWCI
8.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.